We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Cardiology

Cardiology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Sex-Based Patterns and Trends in Transcatheter Aortic Valve Implantation
CardiologyAortic Valve DiseaseCardiology Outcomes

Sex-Based Patterns and Trends in Transcatheter Aortic Valve Implantation

By MedXY|May 10, 2026

A 10-year Medicare study reveals women face higher immediate risks during TAVI procedures but demonstrate better long-term survival than men, despite declining representation in treatment.

Optimizing Antiplatelet Strategies in Complex PCI: Insights from the TAILORED-CHIP Trial and Evolving Evidence for Temporal Modulation
CardiologyAntiplatelet Therapyclopidogrel

Optimizing Antiplatelet Strategies in Complex PCI: Insights from the TAILORED-CHIP Trial and Evolving Evidence for Temporal Modulation

By MedXY|May 12, 2026

This review synthesizes the TAILORED-CHIP trial results with recent evidence on antiplatelet modulation, highlighting the challenges of balancing ischemic and bleeding risks in high-risk PCI populations.

A New hs-cTnT Generation 6 Assay Matches Generation 5 for Myocardial Infarction Diagnosis While Labeling Fewer Patients as Myocardially Injured
CardiologyDiagnostic accuracyemergency department

A New hs-cTnT Generation 6 Assay Matches Generation 5 for Myocardial Infarction Diagnosis While Labeling Fewer Patients as Myocardially Injured

By MedXY|May 9, 2026

In suspected myocardial infarction, hs-cTnT-gen6 showed diagnostic accuracy comparable to gen5, produced fewer myocardial injury classifications, and supported highly sensitive ESC 0/1-hour and 0/2-hour rule-out and rule-in pathways using a

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study
CardiologyanginaFFR

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study

By MedXY|May 9, 2026

ORBITA-FIRE study reveals personalized physiological thresholds for angina that are lower than current diagnostic standards. These thresholds vary during exercise and predict PCI treatment success, challenging universal ischemia-based guide

Optimizing the Referral Pathway for Mechanical Thrombectomy: Evidence-Based Perspectives on Mothership vs. Drip-and-Ship Models
Cardiologyacute ischemic strokeLarge Vessel Occlusion

Optimizing the Referral Pathway for Mechanical Thrombectomy: Evidence-Based Perspectives on Mothership vs. Drip-and-Ship Models

By MedXY|May 12, 2026

This review synthesizes recent evidence comparing ‘mothership’ and ‘drip-and-ship’ strategies in acute ischemic stroke, highlighting functional benefits of direct transport and the critical 43-minute delay threshold.

Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction
CardiologyHFrEFMavacamten

Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction

By MedXY|May 6, 2026

An ex vivo human skeletal muscle study suggests that myosin ATPase inhibition with mavacamten normalizes excessive resting ATP consumption in HFrEF myofibres, identifying a mechanistically novel strategy to address peripheral metabolic inef

AI-ECG Identified Left Ventricular Systolic Dysfunction in Kenya With High Sensitivity and Excellent Rule-Out Performance
AIAI-ECGechocardiography

AI-ECG Identified Left Ventricular Systolic Dysfunction in Kenya With High Sensitivity and Excellent Rule-Out Performance

By MedXY|May 6, 2026

In Kenyan outpatient clinics, an AI-enabled ECG algorithm showed strong discrimination for left ventricular systolic dysfunction, with 95.6% sensitivity and 99.1% negative predictive value against echocardiography.

Long-Term SAFE-PAD Data Reassure on Mortality After Paclitaxel-Coated Femoropopliteal Interventions
Cardiologyfemoropopliteal interventionMortality

Long-Term SAFE-PAD Data Reassure on Mortality After Paclitaxel-Coated Femoropopliteal Interventions

By MedXY|May 6, 2026

In Medicare patients undergoing femoropopliteal revascularization, drug-coated devices were not associated with higher long-term mortality, supporting the safety of paclitaxel-coated technology after years of regulatory concern.

A New Pediatric VAD Driver Shows High Reliability and Preserves Mobility Without Major Device Malfunctions
CardiologyBerlin Heart EXCORDevice Safety

A New Pediatric VAD Driver Shows High Reliability and Preserves Mobility Without Major Device Malfunctions

By MedXY|May 6, 2026

In a prospective multicenter evaluation, the EXCOR Active Driver supported pediatric VAD care with no major device malfunctions and excellent short-term survival, while addressing a major unmet need in mobility and day-to-day function.

Epigenetic Regulation of Myocardial Inflammation: The Role of Macrophage PRMT9 and STAT1 Degradation in Acute Myocardial Infarction
Cardiologymyocardial infarctionPRMT9

Epigenetic Regulation of Myocardial Inflammation: The Role of Macrophage PRMT9 and STAT1 Degradation in Acute Myocardial Infarction

By MedXY|May 12, 2026

This review explores how PRMT9-mediated symmetric dimethylation of STAT1 serves as a critical check on proinflammatory macrophage activation, offering a novel therapeutic target for mitigating cardiac injury following myocardial infarction.

Earlier Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism Improves Hemodynamics but Not In-Hospital Mortality
Cardiologyintermediate-risk PEmechanical thrombectomy

Earlier Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism Improves Hemodynamics but Not In-Hospital Mortality

By MedXY|May 5, 2026

In a multicenter retrospective study, early mechanical thrombectomy within 12 hours of pulmonary embolism diagnosis improved pulmonary artery pressure reduction and reduced intubation, but did not significantly lower in-hospital mortality.

Pulmonary Arterial Hypertension Therapy Preserves Gas Exchange Overall in Portopulmonary Hypertension, but New Intrapulmonary Vascular Dilatations Can Emerge
Cardiologygas exchangehepatopulmonary syndrome

Pulmonary Arterial Hypertension Therapy Preserves Gas Exchange Overall in Portopulmonary Hypertension, but New Intrapulmonary Vascular Dilatations Can Emerge

By MedXY|May 4, 2026

In PoPH, PAH-specific therapy did not worsen oxygenation overall, although responses varied widely. Hemodynamic changes influenced gas exchange, and some patients developed new intrapulmonary vascular dilatations during follow-up.

PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function
CardiologyFamilial HypercholesterolaemiaLDL Cholesterol

PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function

By MedXY|May 3, 2026

In a pooled nonrandomized phase 3 analysis, monthly lerodalcibep reduced LDL-C by about 50% in heterozygous familial hypercholesterolemia, with similar efficacy across LDLR functional variant categories and broad attainment of guideline-bas

Development and Validation of a Clinical Polygenic Risk Report in U.S.-Based Health Systems for 8 Cardiovascular Conditions
CardiologyCardiovascular disease riskpolygenic risk score

Development and Validation of a Clinical Polygenic Risk Report in U.S.-Based Health Systems for 8 Cardiovascular Conditions

By MedXY|May 2, 2026

Researchers developed and validated integrated polygenic risk scores for eight cardiovascular conditions using data from over 245,000 individuals. These scores demonstrated strong predictive power and improved risk classification, providing

GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes
CardiologyDPP‑4 inhibitorsGLP-1 receptor agonists

GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes

By MedXY|May 2, 2026

New research comparing diabetes medications reveals GLP-1 receptor agonists lower heart failure hospitalization risk compared to DPP-4 inhibitors, while showing similar risk to SGLT-2 inhibitors in type 2 diabetes patients.

Late-Life Stroke in ARIC Was More Often Embolic, and Atrial Disease Explained Much of the Risk
Cardiologyatrial fibrillationischemic stroke

Late-Life Stroke in ARIC Was More Often Embolic, and Atrial Disease Explained Much of the Risk

By MedXY|May 1, 2026

In ARIC, ischemic stroke at age 80 years or older was more often embolic than thrombotic. Atrial fibrillation and left atrial disease explained much of the age effect, and adding embolic factors improved prediction.

ATTR-CM Is Often Diagnosed Years After Heart Failure in Medicare Patients
CardiologyATTR-CMdiagnostic delay

ATTR-CM Is Often Diagnosed Years After Heart Failure in Medicare Patients

By MedXY|Apr 30, 2026

In Medicare beneficiaries, ATTR-CM was diagnosed a median 494 days after heart failure and 840 days after loop diuretic initiation, with delays more common in women and patients with several common comorbidities.

Standard-Dose DOACs Outperform Warfarin More Strongly in Asian Than Non-Asian Patients With Atrial Fibrillation
CardiologyAsian patientsatrial fibrillation

Standard-Dose DOACs Outperform Warfarin More Strongly in Asian Than Non-Asian Patients With Atrial Fibrillation

By MedXY|Apr 30, 2026

In a patient-level meta-analysis of 10,212 Asian and 61,471 non-Asian AF patients, standard-dose DOACs outperformed warfarin more strongly in Asians, with less stroke, major bleeding, and net clinical harm. Standard-dose therapy was favored

Coronary Stent Trial Site Selection Could Narrow Racial Gaps in Enrollment, but Women Remain Underrepresented
Cardiologyclinical trial diversitycoronary stents

Coronary Stent Trial Site Selection Could Narrow Racial Gaps in Enrollment, but Women Remain Underrepresented

By MedXY|Apr 30, 2026

In nine U.S. coronary stent PMA trials, minority participants were markedly underrepresented, while women were modestly underrepresented. Site geography and surrounding county demographics predicted minority enrollment, suggesting targeted

Elevated Heart Failure Risk in People With HIV: Insights from the REPRIEVE Trial
Cardiologycardiovascular riskheart failure

Elevated Heart Failure Risk in People With HIV: Insights from the REPRIEVE Trial

By MedXY|Apr 30, 2026

The REPRIEVE trial reveals higher heart failure incidence in people with HIV, particularly among women, Black participants in high-income regions, and those with hypertension or obesity. Traditional risk factors, not HIV-specific markers, w

Prev
21 / 25
1…1920212223…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles